BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts ...
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best new penny stocks to buy. On March 6, AtaiBeckley reported full-year 2025 ...
Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible ...
ATAI, has completed its merger with Beckley Psytech, bringing lead compound BPL-003 fully in house. BPL-003 has received FDA Breakthrough Therapy designation for treatment resistant depression. Recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results